Accelerator, among the financiers looking to kick-start a fledgling biotech hub in New York City, launched its second local project in the form of Lodo Therapeutics, a company working to turn natural products into novel therapies.
Seattle-headquartered Accelerator is aiming to kick-start New York City's nascent biotech ecosystem, leading its group of big-name investors to back a $48 million funding round for a local upstart.
Sean Parker is a very rich man. He has, according to Forbes, about $2.5 billion to his name, and he made most of it by investing in the likes of Napster, Facebook and Spotify. So it was a bit jarring to see the 35-year-old seated next to a pair of renowned cancer experts from Memorial Sloan Kettering and a writer who has won awards for her sober, cogent account of what it's like to be diagnosed with leukemia in your early 20s.
Bristol-Myers Squibb's latest R&D reshuffle calls for a consolidated presence in Cambridge, MA's booming Kendall Square, and the drugmaker has signed on to serve as anchor tenant in the area's next big research facility, joining Big Pharma's ongoing colonization of a biotech hotbed.
Alexandria Real Estate Equities has bagged an anchor tenant with plans to create a big new R&D operation at its Mission Bay biotech cluster bordering the research campus of the University of California San Francisco.
Biogen Idec's ($BIIB) plans to move executive offices back from the Boston burbs to the city of Cambridge, MA, took a step forward yesterday, with Alexandria Real Estate Equities ($ARE) breaking
Alexandria Real Estate Equities has laid plans to build a four-story, 100,000-square-foot biotech lab on Maryland's I-270 corridor--an area that's already thick with developers. The group refused to
Alexandria Real Estate is best known in biotech circles for its U.S. developments. But an Indian newspaper says that the developer is laying out plans for a sprawling R&D complex and life science